IC
HARP

Ikarian Capital’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Ikarian Capital’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,701
Closed -$582K – 218
2022
Q1 		$582K Buy
11,701
+572
+5% +$29.6K 0.08% 126
2021
Q4 		$840K Hold
11,129
– – 0.13% 106
2021
Q3 		$879K Sell
11,129
-231
-2% -$23.2K 0.06% 159
2021
Q2 		$1.58M Sell
11,360
-15,500
-58% -$2.96M 0.13% 145
2021
Q1 		$5.62M Buy
+26,860
New +$5.38M 0.19% 110

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital's HARP Position: Q2 2022 in Review

Ikarian Capital sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 11,701 shares — an estimated $582K sold.

Ikarian Capital first reported a position in HARP in Q1 2021 and held it in 5 quarters. The position peaked at $5.62M in Q1 2021. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • Ikarian Capital reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 11,701 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $582K.
  • Ikarian Capital first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Ikarian Capital's Harpoon Therapeutics, Inc. Common Stock position peaked at $5.62M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.